Home > Neurology > MTIS 2020 > Contents > Real-world evidence reveals physicians’ perception of erenumab

Real-world evidence reveals physicians’ perception of erenumab

Presented By
Dr Mirja Koch, Clinical Research Neuroscience, Novartis Pharma GmbH, Germany
MTIS 2020


The TELESCOPE study provides real-world evidence data for erenumab –a first-in-class calcitonin gene-related peptide (CGRP) receptor inhibitor– in German headache centres. Based on the assessment of treating physicians, erenumab reduced the burden of migraine and increased quality of life (QoL) in >75% of their patients, with onset after the first injection in a majority of the patients.

Erenumab is approved for the preventive treatment of migraine in adults. Real-world data has become increasingly important for providing evidence of treatment effectiveness in clinical practice. TELESCOPE was an online survey, which took place from July until December 2019 in 45 German headache centres, collecting real-world data on erenumab treatment outcome from the physicians’ perception in daily clinical routine [1].

This study captured data on the physician’s perspective on erenumab treatment regarding therapy decision, patient profiles, and QoL in a broad range of migraine patients. In addition, physicians reported treatment effects and satisfaction with the outcome of 10-20 individual episodic and chronic migraine patients with ≥3 months of erenumab treatment per site. The 45 neurologists documented 542 patients.

The majority of neurologists considered restricted QoL (100% of physicians), monthly migraine days (MMDs; 98.8%), and number of previous prophylactic treatments (88.9%) as important reasons for initiating treatment with CGRP mAbs.

Treating physicians observed a reduced migraine burden and an improved QoL after treatment initiation with erenumab. The response rate and patient satisfaction were both reported as high (82.7% and 79.5%, respectively). According to the treating physicians’ reports for all erenumab patients in the last quarter, the following endpoints were reported for erenumab:

  • reduced headache intensity (77.4% of patients);
  • improved QoL (75.5%); and
  • reduced MMDs by half (66%).

Mean change in MMDs was -6.2 (12.1 vs 5.9) and mean change in acute medication days was -6.4 (11.5 vs 5.1). Treating physicians saw a response already after the first injection in 69.4% of patients.


  1. Koch M. Real-world evidence data reveals the physicians’ perception on erenumab therapy in German headache centers. MTIS 2020 Virtual Symposium, abstract MTV20-DP-044.

Posted on